


Supplemental Figure 1



Study schema: A phase I study using belinostat had two parts. Part I of the study evaluated the pharmacokinetic and pharmacodynamics of warfarin in the presence or absence of belinostat (Agarwal et al., 2016). Part II of the study involved evaluating the pharmacokinetics of belinostat and its metabolites in plasma and urine (Bailey et al., 2016). A phase I study of panobinostat in patients with advanced solid tumors and varying degrees of kidney function evaluated the pharmacokinetics of panobinostat in the presence of kidney disease (Sharma et al., 2015). The total number of patients enrolled, number of patients with UC and the responses to treatment are shown in the schema